OHSU researchers identify ocular side effects of commonly prescribed drugs

March 20, 2003

PORTLAND, Ore. - Drugs commonly prescribed to osteoporosis and cancer patients may also cause serious ocular side effects in some cases. That's the conclusion of a study published today by scientists at the Oregon Health & Science University Casey Eye Institute. This research is expected to alert physicians to monitor patients for eye problems not previously associated with the drug. The announcement may also help physicians identify problems earlier, therefore preventing long-term sight damage. Finally, this finding may prompt drug companies to update their product labeling, forewarning physicians and users.

The research, which is printed in the March 20 edition of the New England Journal of Medicine, details how two medications in a class of drugs called bisphosphonates can cause inflammation in several regions of the eye in some patients. Bisphosphonates are used to increase bone density. Loss of bone density is often caused by osteoporosis. Lung, breast or prostate cancer that has spread (metastasized) to the bones can also cause a reduction in bone density. In cancer patients, bisphosphonates are normally provided in conjunction with chemotherapy or other anticancer treatments.

"While these side effects are rare and do not occur in most patients, we consider this a major finding due to the fact that some types of eye inflammation such as scleritis, can cause vision loss or even blindness if gone untreated," explained Frederick Fraunfelder, M.D., an assistant professor of ophthalmology in the OHSU School of Medicine. "The good news for patients is that when caught early, the inflammation can be treated. It's also important to note that the inflammation will dissipate naturally by discontinuation of the medication."

Fraunfelder and his colleagues made this discovery by tracking 314 patients who were prescribed bisphosphonates and also reported eye problems. The cases were located by reviewing thousands of cases where patients were prescribed bisphosphanates. The vast majority of these patients did not suffer serious side effects.

"Of those patients who suffered side effects, almost 100 reported blurred vision while taking the medication," explained Fraunfelder. "Problems reported in other patients included pain and swelling."

Some of the patients in the study are listed in the National Registry of Drug-Induced Ocular Side Effects, a database tracked and updated by the Casey Eye Institute. Physicians worldwide use this reference. An additional database of patient information was provided by the World Health Organization.
-end-
This research was funded by Research to Prevent Blindness, a voluntary organization in support of eye research.

Oregon Health & Science University

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.